ClinicalTrials.Veeva

Menu

Calprotectin I Serum as a Diagnostic Marker

S

St. Olavs Hospital

Status

Completed

Conditions

Pulmonary Disease, Chronic Obstructive

Study type

Observational

Funder types

Other

Identifiers

NCT03474484
20171496/REK midt

Details and patient eligibility

About

Lower respiratory tract infection is the most common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Patients diagnosed with pneumonia in addition to an AECOPD experience more severe clinical and laboratory disease manifestations, increase in-hospital morbidity and worse outcome. Clinicians have sought for new biomarkers that together with clinical assessments can improve the diagnostic accuracy of pneumonia in patients with AECOPD.The aim of the present study is to compare the accuracy of calprotectin with procalcitonin (PCT), C-reactive protein (CRP) and white blood cell count (WBC).

Enrollment

113 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • clinically confirmed acute exacerbation of chronic obstructive pulmonary disorder (AECOPD)
  • COPD diagnosis previously confirmed by spirometry according to the GOLD criteria.

Exclusion criteria

  • known malignant disease
  • bronchiectasis
  • chronic bacterial colonisation of the airways
  • treatment with an immunosuppressive drug or long-term treatment with antibiotics.
  • not examined with a chest X-ray at admission

Trial design

113 participants in 2 patient groups

np-AECOPD
Description:
Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission
p-AECOPD
Description:
Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems